Korean J Pancreas Biliary Tract.  2016 Apr;21(2):101-106. 10.15279/kpba.2016.21.2.101.

A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy

• Choi JE
• Kim KH
• Kim SA
• Lee JH
• Woo SM
• Park SJ
• Hong EK
• Lee WJ

• KMID: 2448522
• DOI: http://doi.org/10.15279/kpba.2016.21.2.101

Abstract

Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a primary liver cancer with histopathologic features of both hepatocelluar carcinoma and cholangiocarcinoma. As combined HCC-CC has been associated with poor outcomes, accurate diagnosis and proper treatment planning for patients are considered to be important for improving survival. Currently, surgery is known as the only treatment modality offering potential cure for localized disease. However, there are little published treatment options for advanced or recurrent disease. Furthermore, no published reports exist in respect to the applying successful curative resection after neoadjuvant therapy for advanced combined HCC-CC. Here, we report a case of combined HCC-CC subtype with stem cell feature, intermediate type who underwent curative surgical resection after neoadjuvant chemotherapy consisting of cisplatin and gemcitabine. Pathologic report revealed negative resection margin and follow-up imaging study shows no evidence of tumor recurrence.

Keyword

Combined hepatocellular-cholangiocarcinoma; Neoadjuvant chemotherapy; Curative resection

MeSH Terms

Cholangiocarcinoma
Cisplatin
Diagnosis
Drug Therapy*
Follow-Up Studies
Humans
Liver Neoplasms
Neoadjuvant Therapy
Recurrence
Stem Cells
Cisplatin